<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00064142</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02925</org_study_id>
    <secondary_id>AMC-036</secondary_id>
    <secondary_id>CDR0000309055</secondary_id>
    <secondary_id>U01CA070019</secondary_id>
    <nct_id>NCT00064142</nct_id>
  </id_info>
  <brief_title>Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma</brief_title>
  <official_title>A Phase II Trial of Topical Halofuginone in Patients With HIV Related Kaposi's Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial studies how well halofuginone hydrobromide works in treating patients&#xD;
      with human immunodeficiency virus (HIV)-related Kaposi's sarcoma. Halofuginone hydrobromide&#xD;
      ointment may stop the growth of Kaposi's sarcoma by stopping blood flow to the tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the tumor response rate of acquired immune deficiency syndrome (AIDS)-related&#xD;
      Kaposi's sarcoma to topical halofuginone (halofuginone hydrobromide) versus vehicle control.&#xD;
&#xD;
      II. To evaluate the safety and tolerability of topical halofuginone and vehicle in patients&#xD;
      with AIDS-related Kaposi's sarcoma.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the ability of topical halofuginone to inhibit expression of matrix&#xD;
      metallopeptidase 2 (MMP-2) and Collagen type I in AIDS-related Kaposi's sarcoma.&#xD;
&#xD;
      II. To explore the relationship between baseline cluster of differentiation (CD) 4 and CD8&#xD;
      counts, HIV viral load and human herpesvirus 8 (HHV-8) viral load and response to&#xD;
      halofuginone.&#xD;
&#xD;
      III. To characterize the pharmacokinetics of halofuginone.&#xD;
&#xD;
      OUTLINE: Twelve treatable Kaposi's sarcoma lesions are selected on each patient, and these 12&#xD;
      lesions are randomized equally to 1 of 2 treatment arms (6 lesions receive study treatment&#xD;
      and 6 lesions receive placebo); each patient serves as his/her own control.&#xD;
&#xD;
      ARM I: Patients apply topical halofuginone hydrobromide ointment to each of 6 lesions twice a&#xD;
      day for 12 weeks.&#xD;
&#xD;
      ARM II: Patients apply topical placebo ointment to each of 6 lesions twice a day for 12&#xD;
      weeks.&#xD;
&#xD;
      Patients with stable or responding disease in either or both groups of treated lesions&#xD;
      (halofuginone hydrobromide ointment or placebo ointment) may receive open-label treatment&#xD;
      with topical halofuginone hydrobromide ointment to all 12 lesions for an additional 12 weeks&#xD;
      as above in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for at least 1 month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>McNemar's chi-square test will be used to compare vehicle control and halofuginone with respect to response rates.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of topical halofuginone as assessed by Common Terminology Criteria for Adverse Events (CTCAE) version 3.0</measure>
    <time_frame>Up to 30 days after completion of treatment</time_frame>
    <description>McNemar's chi-square test will be used to compare the two treatments with respect to the incidence of specific adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in MMP-2 and collagen type I levels</measure>
    <time_frame>From baseline to 4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MMP-2 and collagen type I levels</measure>
    <time_frame>From baseline to 12 weeks</time_frame>
    <description>Changes from baseline in MMP-2 and Collagen type I for halofuginone and vehicle control lesions will be compared using the Wilcoxon rank sum test.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship of CD4, CD8, HIV viral load and HHV-8 viral load on response</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Logistic regression analysis will be used.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>AIDS-related Kaposi Sarcoma</condition>
  <condition>Recurrent Kaposi Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm I (halofuginone hydrobromide)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients apply topical halofuginone hydrobromide ointment to each of 6 lesions twice a day for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients apply topical placebo ointment to each of 6 lesions twice a day for 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>halofuginone hydrobromide</intervention_name>
    <description>Applied topically</description>
    <arm_group_label>Arm I (halofuginone hydrobromide)</arm_group_label>
    <other_name>halofuginone</other_name>
    <other_name>halofuginone HBr</other_name>
    <other_name>RU 19110</other_name>
    <other_name>Tempostatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Applied topically</description>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>PLCB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (halofuginone hydrobromide)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I (halofuginone hydrobromide)</arm_group_label>
    <arm_group_label>Arm II (placebo)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Biopsy-proven Kaposi's sarcoma with at least 14 cutaneous lesions, 12 of which are&#xD;
             measurable in two dimensions and can serve as marker lesions; each of the 14 lesions&#xD;
             must measure a minimum of 0.5 cm in diameter, so that a 4 mm punch biopsy will be&#xD;
             entirely composed of Kaposi's sarcoma&#xD;
&#xD;
          -  Serologic documentation of HIV infection by any of the Food and Drug Administration&#xD;
             (FDA) approved tests&#xD;
&#xD;
          -  Karnofsky performance status &gt;= 60%&#xD;
&#xD;
          -  Hemoglobin &gt;= 8 g/dl&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 750 cells/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 75,000/mm^3&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times the upper limit of normal or creatinine clearance &gt;= 60 mL/min&#xD;
&#xD;
          -  Total bilirubin should be =&lt; 1.5 x upper limit of normal (ULN); if, however, the&#xD;
             elevated bilirubin is felt to be secondary to indinavir therapy, patients will be&#xD;
             allowed to enroll on protocol if the total bilirubin is =&lt; 3.5 mg/dl provided that the&#xD;
             direct bilirubin is normal&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and&#xD;
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =&lt; 3 x&#xD;
             the upper limit of normal&#xD;
&#xD;
          -  Life expectancy &gt;= 3 months&#xD;
&#xD;
          -  Ability and willingness to give informed consent; patients who are younger than 18&#xD;
             years of age will require the consent of a parent or guardian.&#xD;
&#xD;
          -  All women of childbearing potential must have a negative serum b human chorionic&#xD;
             gonadotropin (HCG) within 72 hours prior to study entry and must practice adequate&#xD;
             birth control to prevent pregnancy while receiving treatment and for three months&#xD;
             after treatment is discontinued&#xD;
&#xD;
          -  Patients must, in the opinion of the investigator, be capable of complying with the&#xD;
             protocol&#xD;
&#xD;
          -  Patients receiving antiretroviral therapy must be on a stable regimen for at least 12&#xD;
             weeks prior to study entry without showing evidence of ongoing Kaposi's sarcoma (KS)&#xD;
             regression (ie, less than 25% decrease in the size, number or nodularity of KS lesions&#xD;
             in the opinion of the investigator); patients may receive any FDA approved&#xD;
             antiretroviral therapy or agents available through a treatment IND; concurrent&#xD;
             treatment with highly active antiretroviral therapy should be strongly encouraged, in&#xD;
             accordance with DHHS guidelines (http://www.aids-ed.org/pdfs/adult_2-4-02.pdf) but&#xD;
             will not be required for participation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Concurrent, acute, active, untreated opportunistic infection other than oral thrush or&#xD;
             genital herpes within 14 days of enrollment&#xD;
&#xD;
          -  Known active visceral Kaposi's sarcoma or symptomatic Kaposi's sarcoma-related edema&#xD;
             that interferes with function or requires cytotoxic therapy&#xD;
&#xD;
          -  Concurrent neoplasia requiring cytotoxic therapy&#xD;
&#xD;
          -  Acute treatment for an infection (other than oral thrush or genital herpes) or other&#xD;
             serious medical illness within 14 days of study entry&#xD;
&#xD;
          -  Anti-neoplastic treatment for Kaposi's sarcoma (including chemotherapy, radiation&#xD;
             therapy, local therapy, biological therapy, or investigational therapy) within four&#xD;
             weeks of study entry&#xD;
&#xD;
          -  Previous local therapy of any KS-indicator lesion within 60 days unless the lesion has&#xD;
             clearly progressed since treatment&#xD;
&#xD;
          -  Corticosteroid treatment, other than replacement doses&#xD;
&#xD;
          -  Use of investigational agents other than antiretroviral drugs available under expanded&#xD;
             access or compassionate use protocols&#xD;
&#xD;
          -  Pregnant or breast feeding females are excluded from participation in this study since&#xD;
             the effects of halofuginone on an unborn or young child are unknown and may&#xD;
             potentially be toxic&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan Krown</last_name>
    <role>Principal Investigator</role>
    <affiliation>AIDS Associated Malignancies Clinical Trials Consortium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AIDS - Associated Malignancies Clinical Trials Consortium</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>July 8, 2003</study_first_submitted>
  <study_first_submitted_qc>July 8, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2003</study_first_posted>
  <last_update_submitted>June 4, 2013</last_update_submitted>
  <last_update_submitted_qc>June 4, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma, Kaposi</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Halofuginone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

